ABOUT MICROBIO

2004

A novel pathogen identification approach using DNA ‘fingerprints’

Dr Flavia Huygens has developed and validated a process that uses Single Nucleotide Polymorphisms (SNPs) to delineate bacterial populations by mathematically maximising the resolving power of these SNPs. The test homes in on these SNPs, the pathogen’s DNA ‘fingerprint’, found at a specific point in its genetic code. By focusing on SNPs rather than the whole genome, the process is fast, inexpensive, highly sensitive and can be adapted to address different target pathogens.

To date, this approach has been successfully applied to characterise several bacterial pathogens including Staphylococcus aureus, Neisseria meningitidis, Campylobacter jejunii, Streptococcus agalactiae, Escherichia coli, Enterococcus faecalis and Enterococcus faecium. This technology was considered a world-first and is unique in its design and application, leading to several
publications.

The test was refined and became InfectID, which uses real-time PCR followed by high-resolution melt-curve analysis (MCA) to identify pathogen species directly from whole blood without the need to pre-culture.

2015

Clinical research demonstrates the approach’s specificity

In 2015, Dr Huygens led a collaborative trial with the Microbiology Central Laboratory, Pathology
Queensland, which involved testing 300 patient samples: 100 negative samples
and 200 positive samples. The study found that InfectID had a specificity of 98.5% in correctly
identifying bacterial species from blood samples.

 

2018

Microbio founded to take InfectID to market

Microbio was founded in 2018 by Dr Huygens and Paul Carboon. Their aim was to build a scientific and commercialisation team to bring Microbio’s pathogen diagnostic test out of the laboratory and into the market to benefit human health and wellbeing.

2019

Seed funding raised to conduct preclinical verification

An initial funding round provided the capital to establish the laboratory research team. Preclinical testing began on patient whole blood samples in two Queensland Hospitals. Early results indicate >99% specificity for the 25 most common sepsis-causing pathogens:

Gram-Negative Bacteria
Escherichia coli
Enterobacter cloacae
Serratia marcescens
Proteus mirabilis
Klebsiella pneumoniae
Klebsiella aerogenes
Haemophilus influenzae
Pseudomonas aeruginosa
Citrobacter freundii
Acinetobacter baumannii
Stenotrophomonas maltophilia
Gram-Positive Bacteria
Enterococcus faecalis
Enterococcus faecium
Streptococcus agalactiae
Streptococcus pyogenes
Streptococcus pneumoniae
Streptococcus anginosus
Streptococcus bovis
Staphylococcus epidermidis
Staphylococcus aureus
Yeast
Candida albicans
Candida tropicalis
Candida krusei
Candida parapsilosis
Candida glabrata

 

2020

Establish the Microbio team

A Series A capital raise closed on 30 September 2020. This funding will allow for the continued growth of the team to facilitate the commercialisation of InfectID. The emergence of COVID-19 motivated the team to develop a SARS-CoV-2 test designed to identify the presence of replicating virus.